Business
Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile
Rznomics announced today that it presented interim clinical data from its ongoing study of RZ-001, an RNA editing-based investigational anticancer therapy, in patients with hepatocellular carcinoma (HCC) during an oral presentation at the AACR 2026 (American Association for Cancer Research Annual Meeting), held on April 19, 2026, in San Diego, California.
About this update from Rznomics Inc.
[{"type":"text","content":"– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed)","length":63,"tagName":"p"},{"type":"text","content":"– mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23%","length":70,"tagName":"p"},{"type":"text","content":"– No Grade 3 or higher adverse events related to RZ-001 observed","length":64,"tagName":"p"},{"type":"text","content":"– Highlights clinical potential of RNA trans-splicing ribozyme platform technology","length":82,"tagName":"p"},{"type":"text","content":"SEOUL, South Korea, April 20, 2026 /PRNewswire/ -- Rznomics announced today that it presented interim clinical data from its ongoing study of RZ-001, an RNA editing-based investigational anticancer therapy, in patients with hepatocellular carcinoma (HCC) during an oral presentation at the AACR 2026 (American Association for Cancer Research Annual Meeting), held on April 19, 2026, in San Diego, California.","length":413,"tagName":"p"},{"type":"image","alt":"Rznomics Inc. logo","displaySize":"","headline":null,"caption":"Rznomics Inc. logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":112,"url":"https://media.zenfs.com/en/prnewswire.com/f7ff902d0dacca8515c91d28e54f7652"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zh_VGfx.9g88e0qrdZhe2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5Nw--/https://media.zenfs.com/en/prnewswire.com/f7ff902d0dacca8515c91d28e54f7652","width":400,"height":112}},"href":"https://mma.prnewswire.com/media/2961309/RznomicsLogo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The presentation was delivered by Professor Yoon-Jun Kim of the Department of Gastroenterology at Seoul National University Hospital.","length":133,"tagName":"p"},{"type":"text","content":"The study includes patients with HCC who are refractory to or ineligible for transarterial chemoembolization (TACE) and have not received prior systemic therapy.","length":161,"tagName":"p"},{"type":"text","content":"According to the data presented, combination treatment of RZ-001 with atezolizumab and bevacizumab demonstrated an objective response rate (ORR) of 38.5% (confirmed) and 46.2% (unconfirmed) based on RECIST v1.1 criteria.","length":220,"tagName":"p"},{"type":"text","content":"Under mRECIST criteria, the ORR reached 61.5%, with a complete response (CR) rate of 23%, suggesting deep tumor re...